Pursuant to section 5(3)(b) of the COVID-19 Public Health Response Act 2020, I, Dr Ashley Bloomfield, Director-General, Ministry of Health, hereby declare that the doses of each COVID-19 vaccine or combination of COVID-19 vaccines specified in the Schedule to this notice are required for a person to be “vaccinated” for the purposes of all or any legislation in, or made under, the COVID-19 Public Health Response Act 2020 that uses this defined term.

For the avoidance of doubt, the schedule does not apply to vaccination obligations under the COVID-19 Public Health Response (Air Border) Order (No 2) 2020.

Schedule – Doses and Type of Vaccine Required to be Treated as Fully Vaccinated Within New Zealand Borders

2 doses of Pfizer/BioNTech (Comirnaty, Tozinameran, BNT162b2)

2 doses of Moderna (Spikevax, mRNA-1273)

2 doses of AstraZeneca (Covishield)

2 doses of Moderna (Spikevax, mRNA-1273)

2 doses of Sinopharm, Beijing (BBIBP-CorV, Sinopharm COVID-19 vaccine, BIBP vaccine, Covilo)

2 doses of Sinovac (CoronaVac, Sinovac COVID-19 vaccine, PiCoVacc).

2 doses of Bharat Biotech (Covaxin, BBV152)

1 dose of Janssen / Johnson & Johnson (Janssen COVID-19 Vaccine, Ad26.COV2.S, Ad26COVS1, JNJ-78436735), alone or in combination with any other vaccine

2 doses of any combination of the following:

• Pfizer/BioNTech (Comirnaty, Tozinameran, BNT162b2)
• Moderna (Spikevax, mRNA-1273)
• AstraZeneca (Vaxzevria, AZD1222)
• AstraZeneca (Covishield)
• Sinopharm, Beijing (BBIBP-CorV, Sinopharm COVID-19 vaccine, BIBP vaccine, Covilo)
• Sinovac (CoronaVac, Sinovac COVID-19 vaccine, PiCoVacc)
• Bharat Biotech (Covaxin, BBV152)

If a person has received 1 or 2 doses (or for Zydus Cadila, 1, 2 or 3 doses) of any of the following, then 1 additional dose of Pfizer/BioNTech, Moderna, AstraZeneca (Vaxzevria or Covishield) or Janssen vaccine is required to be treated as fully vaccinated.

If this additional dose is administered in New Zealand it should be given more than 28 days after previous COVID-19 vaccine dose.

• Sinopharm, Wuhan (Sinopharm/WIBP COVID-19 vaccine)
• Gamaleya Research Institute of Epidemiology and Microbiology (Sputnik V, Gam-COVID-Vac)
• Gamaleya Research Institute of Epidemiology and Microbiology (Sputnik light)
• Takeda (TAK-919, COVID-19 Vaccine Moderna Intramuscular Injection). Note: this is a Moderna formulation
• CanSino (Convidecia, PakVac, Ad5-nCoV)
• Zydus Cadila (ZyCoV-D)
• Anhui Zhifei Longcom (Zifivax, ZF2001, ZF-UZ-VAC-2001)
• Beijing Minhai Biotechnology Co (KCONVAC, Minhai COVID-19 vaccine)
• Shifa Pharmed Industrial Co (COVIran Barekat, COVIRAN)
• Federal Budgetary Research Institution State Research Center of Virology and Biotechnology VECTOR, FBRI (EpiVacCorona)
• Chumakov Centre (KoviVac)
• Khazakstan Research Institute for Biological Safety Problems, RIBSP (QazVac, QazCovid-in)
• Medigen Vaccine Biologics Corporation, MVC (MVC COVID-19 vaccine, Medigen COVID-19 vaccine MVC-COV1901)
• Center for Genetic Engineering and Biotechnology, CIGB (Abdala, CIGB-66)
• Vaxine/Cinna Gen Co. COVAX-19 (SpikeoGen)
• Covovax (Serum Institute of India, Novavax formulation)

Dated at Wellington this 26th day of November 2021.

Dr ASHLEY BLOOMFIELD, Director-General of Health.